Skip to main content
HHS Logo U.S. Department of Health & Human Services Divider arrow NIH logo National Institutes of Health Alt desc
Assay Development and Screening Technology

ADST in Action

At NCATS, the experts in the Assay Development and Screening Technology (ADST) program work to optimize assays requested or submitted by the biomedical research community for high-throughput small-molecule screening. Read the latest news about this program below. 

June 2015

Partnering with Disease Foundations to Speed Drug Discovery

When scientists who specialize in drug development have a promising idea for a new disease treatment, they often start by designing biological tests called assays. By using high-throughput (robotically assisted) screening, researchers use the assays to evaluate hundreds of thousands of compounds with the potential to become new treatments. This complex process requires teamwork to involve the right types of expertise and perspectives in the research project team.

November 2014

NCATS Screening Technologies Enable Identification of Potential Treatment Target for Neurological Disorder

A collaboration involving a patient advocacy group, pharmaceutical companies, academic researchers and ADST program experts culminated in an innovative advance in drug discovery technology, enabling the group to identify a potential new drug target for one of the most common forms of an inherited neurological disorder called Charcot-Marie-Tooth disease. (See July 2012.)

July 2014

Michael J. Fox Foundation Funds Research Project that Leverages NCATS Chemical Screening Approach and Resources

With support from the Michael J. Fox Foundation for Parkinson’s Research, experts at NCATS and the National Institute of Neurological Disorders and Stroke are leading a project that showcases how NCATS’ chemical screening resources can advance development of potential therapeutics for a broad range of diseases, including Parkinson’s disease.

November 2012

A New Method to Help Scientists Better Identify Drug Candidates

ADST program researchers designed a novel method that increases the odds of identifying candidate compounds with true activity against biological or disease targets, an advance that will better equip scientists to understand diseases and develop effective therapeutics.

July 2012

Collaboration May Help Uncover Treatments for Rare Neurologic Disease

A research collaboration including scientists from the ADST program and the University of Wisconsin–Madison helped identify three promising molecular compounds from a collection of approved drugs to pursue as potential treatments for Charcot-Marie-Tooth disease, a genetic neurological disease for which there are currently no treatments.